Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Artemis Investment Management LLP

Artemis Investment Management LLP reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 34.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,211 shares of the medical equipment provider’s stock after selling 1,716 shares during the quarter. Artemis Investment Management LLP’s holdings in Hologic were worth $231,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Federated Hermes Inc. purchased a new position in Hologic during the second quarter worth about $246,000. Envestnet Asset Management Inc. raised its stake in shares of Hologic by 3.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 361,271 shares of the medical equipment provider’s stock worth $26,824,000 after buying an additional 12,671 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Hologic by 31.1% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 72,220 shares of the medical equipment provider’s stock valued at $5,362,000 after buying an additional 17,130 shares during the period. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Hologic by 22.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 24,587 shares of the medical equipment provider’s stock valued at $1,826,000 after buying an additional 4,429 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in Hologic by 48.7% during the second quarter. Intech Investment Management LLC now owns 60,486 shares of the medical equipment provider’s stock worth $4,491,000 after acquiring an additional 19,799 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on HOLX. Evercore ISI boosted their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Leerink Partners decreased their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Royal Bank of Canada raised their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. upped their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $88.92.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.75% of the stock is owned by insiders.

Hologic Stock Down 0.3 %

HOLX stock opened at $69.73 on Monday. The company has a 50 day moving average price of $74.84 and a two-hundred day moving average price of $78.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market capitalization of $15.82 billion, a P/E ratio of 20.94, a PEG ratio of 2.44 and a beta of 0.97. Hologic, Inc. has a one year low of $68.61 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the business earned $0.89 earnings per share. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.